From the University of Texas Southwestern; Baylor Research Institute; Baylor Heart and Vascular Institute; Texas A&M HSC College of Medicine, Dallas, Texas, USA.
B.S. Mills, MD, University of Texas Southwestern; K.H. Dao, MD, Baylor Research Institute; K.M. Tecson, PhD, Baylor Research Institute, and Baylor Heart and Vascular Institute; E.F. Beil, MD, Texas A&M HSC College of Medicine; R. Tate, MD, Baylor Research Institute; J.J. Cush, MD, Baylor Research Institute.
J Rheumatol. 2020 Jan;47(1):149-154. doi: 10.3899/jrheum.181067. Epub 2019 Apr 1.
The Pregnancy and Lactation Autoimmune Network (PLAN) registry was established to evaluate the concerns of women with autoimmune or inflammatory rheumatic diseases (AIRD) pertaining to pregnancy and lactation.
The registry was started as a survey of patients with AIRD at a single rheumatology specialty center in November 2016 and included questions regarding fertility, pregnancy, miscarriages, and lactation before and after diagnosis.
The study included 154 subjects from the PLAN registry. More than half (52%) of respondents indicated that their diagnosis negatively changed their views on pregnancy and nearly a third (30%) decided not to have children after AIRD diagnosis. Most (66%) women were concerned that medication use during the childbearing process would affect the baby. One-third (34%) indicated their views on breastfeeding negatively changed as a result of their disease diagnosis. The rates and duration of breastfeeding did not differ significantly for babies born before or after the mothers' diagnosis (p = 0.50 and p = 0.21, respectively). Eighteen women in our study avoided breastfeeding or stopped breastfeeding earlier than planned to start a medication (including etanercept, adalimumab, hydroxychloroquine, and certolizumab) they believed to be contraindicated during lactation. The PLAN registry included 19 women who breastfed 22 babies while being exposed to a disease-modifying antirheumatic drug or biologic. None of these 19 women reported a delay in their children's developmental milestones or higher infection rates.
This study highlights an unmet need in patients with AIRD of childbearing potential for data and education regarding pregnancy and lactation.
妊娠和哺乳期自身免疫网络 (PLAN) 登记处的成立旨在评估患有自身免疫或炎症性风湿病 (AIRD) 的女性对妊娠和哺乳期的担忧。
该登记处于 2016 年 11 月作为一家风湿病专科中心的患者调查开始,包括与诊断前后生育、妊娠、流产和哺乳相关的问题。
该研究纳入了 PLAN 登记处的 154 名受试者。超过一半(52%)的受访者表示,他们的诊断改变了他们对妊娠的看法,近三分之一(30%)在诊断出 AIRD 后决定不要孩子。大多数(66%)女性担心在生育过程中使用药物会影响婴儿。三分之一(34%)的人表示,由于疾病诊断,他们对母乳喂养的看法发生了变化。母亲诊断前后出生的婴儿的母乳喂养率和持续时间无显著差异(p = 0.50 和 p = 0.21)。在我们的研究中,有 18 名女性为避免开始使用被认为在哺乳期禁忌的药物(包括依那西普、阿达木单抗、羟氯喹和certolizumab)而避免母乳喂养或提前停止母乳喂养。PLAN 登记处包括 19 名在接触疾病缓解抗风湿药物或生物制剂时母乳喂养 22 名婴儿的女性。这 19 名女性均未报告其子女发育里程碑延迟或感染率升高。
这项研究强调了具有生育潜力的 AIRD 患者在妊娠和哺乳方面需要数据和教育。